Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia from ...

Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the ...

Prostate cancer is often resistant to immunotherapy, which harnesses a person's immune system to recognize and destroy tumors ...

Not all cancers are alike, especially when it comes to prostate cancer. “The guidelines recommend they go on active surveillance rather than getting treated. For many of them, it’s really unlikely ...

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

When prostate cancer has spread beyond the prostate to nearby lymph nodes and other areas of the body and treatments can no longer slow or stop its growth, you are not alone. Many patients, despite ...

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...